Screener
AbCellera Biologics Inc. ABCL Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from AbCellera Biologics Inc.’s reported figures.
Based on the most recent quarter.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s debt-to-equity?
- AbCellera Biologics Inc. (ABCL) reported debt-to-equity of 0.2× in Q2 2026.
- How has AbCellera Biologics Inc.'s debt-to-equity changed year-over-year?
- AbCellera Biologics Inc.'s debt-to-equity increased by 7.3% year-over-year, from 0.1× to 0.2×.
- What is the long-term trend for AbCellera Biologics Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s debt-to-equity has grown at a 93.2% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about AbCellera Biologics Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude